Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05259072 · ClinicalTrials.gov registry record
carDIo-ttranSSfOrm nucLEar Imaging Study
A clinical trial, sponsored by Oregon Health and Science University.
- Terminated
- Registry status
- 4
- Enrollment target
NCT05259072 is a clinical trial that was terminated before completion, run by Oregon Health and Science University. The registered enrollment target is 4 participants.
The verdict
NCT05259072 was terminated before completion, sponsored by Oregon Health and Science University.
- TERMINATED
- Registry status
- 4 participants
- Enrollment target
Study Summary
The investigators will evaluate the change in myocardial uptake of 99m-technetium pyrophosphate (Tc-99m PYP) tracer on serial planar and SPECT imaging in patients enrolled in the CARDIO-TTRansform clinical trial (NCT04136171).
Interventions
- DIAGNOSTIC_TEST 99m-technetium pyrophosphate scintigraphy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2022-01-19 |
| Est. Completion | 2023-12-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05259072
The ClinicalTrials.gov registry entry for NCT05259072 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Oregon Health and Science University, which has 546 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 99m-technetium pyrophosphate scintigraphy is the first listed.
NCT05259072 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05259072 about?
NCT05259072 is a clinical study titled "carDIo-ttranSSfOrm nucLEar Imaging Study". The investigators will evaluate the change in myocardial uptake of 99m-technetium pyrophosphate (Tc-99m PYP) tracer on serial planar and SPECT imaging in patients enrolled in the CARDIO-TTRansform clinical trial (NCT04136171).
What is the current status of trial NCT05259072?
This trial is currently terminated. The enrollment target is 4 participants. The study started on 2022-01-19. Estimated completion is 2023-12-30.
What interventions are being tested in trial NCT05259072?
The interventions under investigation include: 99m-technetium pyrophosphate scintigraphy (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05259072?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.